These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


210 related items for PubMed ID: 10637255

  • 1. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party.
    Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ.
    J Clin Oncol; 2000 Jan; 18(2):395-404. PubMed ID: 10637255
    [Abstract] [Full Text] [Related]

  • 2. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
    Thatcher N, Clark PI, Smith DB, Anderson H, Girling DJ, Machin D, Stephens RJ, Lallemand G, Jenkins B.
    Clin Oncol (R Coll Radiol); 1995 Jan; 7(5):293-9. PubMed ID: 8580054
    [Abstract] [Full Text] [Related]

  • 3. The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Medical Research Council Lung Cancer Working Party.
    Thatcher N, Anderson H, Bleehen NM, Girling DJ, Lallemand G, Machin D, Stephens RJ.
    Eur J Cancer; 1995 Jan; 31A(2):152-6. PubMed ID: 7536433
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R, Weiss GR, Hicks WJ, Gandara DR.
    J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
    [Abstract] [Full Text] [Related]

  • 6. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
    Michel G, Landman-Parker J, Auclerc MF, Mathey C, Leblanc T, Legall E, Bordigoni P, Lamagnere JP, Demeocq F, Perel Y, Auvrignon A, Berthou C, Bauduer F, Pautard B, Schneider P, Schaison G, Leverger G, Baruchel A.
    J Clin Oncol; 2000 Apr; 18(7):1517-24. PubMed ID: 10735900
    [Abstract] [Full Text] [Related]

  • 7. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
    Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, Dziadziuszko R, Burghouts J, Van Meerbeeck JP, Gans S, Legrand C, Debruyne C, Giaccone G, Manegold C, European Organization for Research and Treatment of Cancer-Lung Cancer Group.
    J Clin Oncol; 2002 Oct 01; 20(19):3947-55. PubMed ID: 12351591
    [Abstract] [Full Text] [Related]

  • 8. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, Termeer A, Hensing CA, Akkermans J, Adang EM, Bootsma GP, Tjan-Heijnen VC.
    J Clin Oncol; 2005 Nov 01; 23(31):7974-84. PubMed ID: 16258098
    [Abstract] [Full Text] [Related]

  • 9. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun 01; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

  • 10. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G.
    N Engl J Med; 1991 Jul 18; 325(3):164-70. PubMed ID: 1711156
    [Abstract] [Full Text] [Related]

  • 11. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
    Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F, Kaiser G.
    J Clin Oncol; 1994 Dec 18; 12(12):2667-76. PubMed ID: 7989942
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.
    Hanauske AR, Korfel A, Perker M, Heinrich B, Schwab G, Graf M, Depenbrock H, Höffken G, Kreuser ED, Thiel E, Zwingers T, Berdel WE.
    Oncology; 1997 Dec 18; 54(5):363-70. PubMed ID: 9260596
    [Abstract] [Full Text] [Related]

  • 14. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL, Douillard JY, Rivière A, Quoix E, Lagrange JL, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T.
    J Clin Oncol; 1997 May 18; 15(5):2082-9. PubMed ID: 9164221
    [Abstract] [Full Text] [Related]

  • 15. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov 18; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 16. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J.
    J Clin Oncol; 1998 Feb 18; 16(2):642-50. PubMed ID: 9469353
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
    Hesketh PJ, McCoy J, Dunphy FR, Bearden JD, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K, Crowley JJ, Gandara DR.
    J Thorac Oncol; 2006 Nov 18; 1(9):991-5. PubMed ID: 17409984
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D.
    J Clin Oncol; 1996 Aug 18; 14(8):2345-52. PubMed ID: 8708727
    [Abstract] [Full Text] [Related]

  • 19. High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.
    Ardizzoni A, Venturini M, Crinò L, Sertoli MR, Bruzzi P, Pennucci MC, Mariani GL, Garrone O, Bracarda S, Rosso R.
    Eur J Cancer; 1993 Aug 18; 29A(5):687-92. PubMed ID: 8385970
    [Abstract] [Full Text] [Related]

  • 20. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC.
    J Clin Oncol; 1994 Oct 18; 12(10):2022-34. PubMed ID: 7931470
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.